Clinical trial
The Feasibility, Safety and Efficacy Evaluation of Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System for the Treatment of Coronary Heart Disease: a First-in-man Study
NCT02844270 is registered in ClinicalTrials.gov with Shanghai Bio-heart Biological Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Feasibility, Safety and Efficacy Evaluation of Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System for the Treatment of Coronary Heart Disease: a First-in-man Study
- Lead sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- August 9, 2016
- Completion date
- December 31, 2021
- Enrollment
- 45 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.